Ge Healthcare Technologies Inc.
GE HealthCare Announces Pricing of Secondary Offering
Summary
GE HealthCare Technologies Inc. announced the pricing of a secondary offering of 13,281,302 shares of its common stock on November 7, 2024. The company will not sell any shares and will not receive any proceeds from the sale. Instead, GE Aerospace is expected to exchange the shares for its indebtedness held by Morgan Stanley Bank, N.A., and subsequently, Morgan Stanley & Co. LLC intends to sell the shares to underwriters. The offering is expected to close on November 12, 2024, subject to customary conditions.
Profitelligence Alerts
Get alerts for GEHC
Be first to know when Ge Healthcare Technologies Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc. is a prominent player in the healthcare industry, focused on providing transformative medical technology and diagnostic solutions. Specializing in imaging, monitoring, and diagnostic equipment, the company plays a crucial role in enhancing clinical outcomes, improving patient care, and driving medical technology innovations. Ge Healthcare Technologies Inc. is recognized for its advancements in medical imaging systems, including MRI, CT, and ultrasound technologies, which aid in early disease detection and treatment planning. In addition to its hardware innovations, the company is actively involved in digital healthcare solutions, employing data analytics and AI to support precise diagnoses and personalized medicine. The impact of Ge Healthcare Technologies extends across various healthcare sectors, including hospitals, clinics, and research institutions, underscoring its importance in advancing clinical capabilities and operational efficiencies within the healthcare system. Ge Healthcare Technologies Inc. maintains a strategic presence in global markets, bolstering healthcare infrastructure and supporting public health initiatives. By continuously striving to innovate and improve healthcare delivery, it remains a significant entity within the broader medical technology and life sciences industry, contributing to the future of healthcare.
Official SEC Documents
Advertisement